Ghoul
Member
Four recent FDA Warning Letters involving sales of US domestic peptides:
Xcel Peptides - Xcel Research LLC - 694608 - 12/10/2024
Prime Peptides - Prime Vitality, Inc. dba Prime Peptides - 695156 - 12/10/2024
Summit Peptides - Summit Research Peptides - 695607 - 12/10/2024
SwissChems - Swisschems - 695663 - 12/10/2024
(SwissChems has been an established vendor - though always with mixed, sketchy reviews - for nootropics, SARMS, and Research Chemicals for many years.)
This set of FDA Warning Letters seems to involve:
1. The classic mistake where vendors include any language that indicates products may be sold for human use.
(For example, product descriptions & product labels with statements about health benefits, medical use cases, dose size/schedule, how to administer.)
2. Attention on peptide product keywords. In these cases, "SEMAGLUTIDE", "TIRZEPATIDE", "RETATRUTIDE", "TESAMORELIN", and other generic, non-branded peptide names.

Key phrase. Without this, no action could've been taken. They're not controlled substances. That's why places like Peptide Science doesn't have this problem and hasn't for over a decade. They're not sloppy. Hell, they're insanely paranoid about avoiding the slightest hint of "human use".
You can buy urea by the ton. Make a prescription strength foot cream out of it and start marketing it as a cure for dry skin, and now it's "for human use" and the FDA can respond. You can buy Ivermectin for your livestock. no prescription required. Offer it for people and once again the line has been crossed.
